← Trials/Trial dossier/NCT00867399

CompletedPhase 1

A Safety and Tolerability Study of ABT-126 in Elderly

A Multiple Dose Study of Safety, Tolerability and Pharmacokinetics of ABT-126 in Elderly Subjects

Lead sponsor

Abbott

Asset

ABT-126

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criterion

•MMSE 27

Primary endpoints

•Safety and Tolerability Assessments•Assess the Pharmacokinetics

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDM10-717

NCT IDNCT00867399

Timeline

Milestones

Study start2009-03 (month precision)

Study first posted2009-03-23estimated

Primary completion2009-05actual (month precision)

Last update posted2010-11-02estimated

Assets

Drug assets

ABT-126

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Healthy male or female subjects 65 years or greater.

•Has a MMSE score of 27 or higher

Exclusion criteria

•History of dementia including by not limited to Alzheimer's disease, Parkinson's disease and mult-infarct dementia.

•History of any significant neurological disease.

•Has an estimated creatinine clearance < 30 mL/min

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

Safety and Tolerability Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)

Time frame:Study Days -1 thru Day 28

descriptive

Primary/protocol endpoint

Assess the Pharmacokinetics

Time frame:Study Days -1 thru Day 28

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.